Published Nov 8, 2022

What Promise Do Psychedelics Hold As Therapeutics?

Dive into the therapeutic potential of psychedelics with insights from Albert Garcia-Romeu, a researcher at Johns Hopkins University, as he explores how substances like MDMA, psilocybin, and ketamine could revolutionize mental health treatment amid societal curiosity and cautious optimism.
Episode Highlights
Chasing Life logo

Popular Clips

Episode Highlights

  • Rapid Effects

    Psychedelics like ketamine and psilocybin show promise in rapidly alleviating depression. explains that ketamine can improve severe depression symptoms within 24 hours, and psilocybin offers similar rapid effects 1. These substances promote neuroplasticity, fostering new brain connections, particularly in the prefrontal cortex, which may explain their lasting benefits 1. highlights the intriguing long-term impact of psilocybin, noting that some patients experience months of antidepressant effects after just one or two doses 1.

       

    Lasting Benefits

    The enduring benefits of psychedelics are a key area of interest. notes that psilocybin can provide antidepressant effects lasting up to a year, unlike ketamine, which typically requires more frequent dosing 1. He suggests that the profound psychological experiences induced by psychedelics might contribute to these lasting changes, akin to 'trauma in reverse' 2. finds the sporadic dosing schedule of psychedelics intriguing, as it contrasts with the daily regimen required by traditional antidepressants 2.

       

    Safety & Access

    Safety and accessibility are crucial considerations in psychedelic therapy. advises caution for individuals with a history of psychotic disorders or bipolar mania, as psychedelics could exacerbate these conditions 3. He emphasizes that while psychedelics are generally safe, they can lead to challenging experiences, though not fatal overdoses like opioids 3. Accessibility remains a challenge, with current research predominantly involving higher socioeconomic groups, raising concerns about equitable access to these therapies once approved 4.

Related Episodes